Skip to main content
Top
Published in: European Journal of Nuclear Medicine and Molecular Imaging 5/2022

01-04-2022 | Editorial

Highlights of the 34th EANM Annual Congress 2021, 2nd virtual edition: “FROM HAMBURG WITH LOVE”

Authors: Nathalie L. Albert, Irene A. Burger

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 5/2022

Login to get access

Excerpt

The 34th Annual Congress of the European Association of Nuclear Medicine (EANM) was planned to take place in Hamburg, Germany. However, due to the persisting SARS-CoV-2 pandemic, the second virtual edition took place from the 20th to the 23rd of October under the chairmanship of Professor Fanti. Despite the hope of the organizers, as well as the participants to be able to have a real “face-to-face” meeting again, everybody was dedicated to generate scientifically outstanding content, with over 1200 submitted abstracts from 59 different countries. The ease of accessibility allowed 2810 participants to join the congress from anywhere globally (from 110 countries), reaching more than 175,000 hits on the virtual platform during the 3.5 congress days. Some of the popular sessions were viewed over 3100 times; furthermore, the continued availability to view the educational contents and CME sessions allowed prolonged access to the high-quality lectures and was still frequently used in the first week of December. Overall, among the 1272 submitted abstracts, 1088 (1034 scientific, 54 technologists) were accepted with 623 abstracts considered for oral presentations and 313 rated as potential highlights by the reviewers of the respective subcommittees. Like last year, EU countries including Italy (13%), Spain (9.6%), Germany (8.8%), and France (7.3%) submitted the greatest number of abstracts. The non-EU country contributing most abstracts this year was Turkey (6%) (Fig. 1).
Literature
1.
2.
go back to reference Tschan VJ, et al. Impact of the mouse model and molar amount of injected ligand on the tissue distribution profile of PSMA radioligands. Eur J Nucl Med Mol Imaging; 2021. Tschan VJ, et al. Impact of the mouse model and molar amount of injected ligand on the tissue distribution profile of PSMA radioligands. Eur J Nucl Med Mol Imaging; 2021.
3.
go back to reference Grzmil M, et al. Pharmacological inhibition of mTORC1 increases CCKBR-specific tumor uptake of radiolabeled minigastrin analogue [(177)Lu]Lu-PP-F11N. Theranostics. 2020;10(24):10861–73.CrossRef Grzmil M, et al. Pharmacological inhibition of mTORC1 increases CCKBR-specific tumor uptake of radiolabeled minigastrin analogue [(177)Lu]Lu-PP-F11N. Theranostics. 2020;10(24):10861–73.CrossRef
5.
go back to reference Xiang X, et al. Microglial activation states drive glucose uptake and FDG-PET alterations in neurodegenerative diseases. Sci Transl Med. 2021;13(615):eabe5640.CrossRef Xiang X, et al. Microglial activation states drive glucose uptake and FDG-PET alterations in neurodegenerative diseases. Sci Transl Med. 2021;13(615):eabe5640.CrossRef
6.
go back to reference Denize T, et al. Biomarkers of angiogenesis and clinical outcomes to cabozantinib and everolimus in patients with metastatic renal cell carcinoma from the phase III METEOR trial. Clin Cancer Res; 2021. Denize T, et al. Biomarkers of angiogenesis and clinical outcomes to cabozantinib and everolimus in patients with metastatic renal cell carcinoma from the phase III METEOR trial. Clin Cancer Res; 2021.
7.
go back to reference Shen R, et al. LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. Sci Transl Med. 2021;13(608). Shen R, et al. LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. Sci Transl Med. 2021;13(608).
8.
go back to reference Hofman MS, et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797–804.CrossRef Hofman MS, et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797–804.CrossRef
Metadata
Title
Highlights of the 34th EANM Annual Congress 2021, 2nd virtual edition: “FROM HAMBURG WITH LOVE”
Authors
Nathalie L. Albert
Irene A. Burger
Publication date
01-04-2022
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 5/2022
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-022-05724-w

Other articles of this Issue 5/2022

European Journal of Nuclear Medicine and Molecular Imaging 5/2022 Go to the issue